Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients

T. Šálek, A. Adamíková,

. 2019 ; 124 (3) : 298-302. [pub] 20181017

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035015

The aim of this study was to provide evidence for the hypothesis that estimated glomerular filtration rate from serum Cystatin C (eGFRcys) is better to be determined for all elderly type 2 diabetes mellitus (T2DM) patients based on eGFRcys upward and downward reclassification rate for hypothetical metformin dose reduction by eGFRcys at the GFR decision point of 45 mL/min/1.73 m2 . A total of 265 consecutive T2DM elderly patients (age range 65-91 years) from outpatient diabetic clinic were included in the study. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines for metformin dosing were strictly followed. Estimated glomerular filtration rate from serum creatinine (eGFRcrea) led to results of metformin eligibility. Each of the results of eGFRcrea-based eligibility was further compared to eGFRcys-based eligibility. Creatinine was measured by enzymatic method standardized against international reference material SRM 967. Cystatin C was determined by method traceable to DA ERM 471 international standard. eGFRcrea and eGFRcys were calculated according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. A downward reclassification rate was higher than upward reclassification rate (31 vs 3, respectively; P < 0.0001). The median (IQR) eGFRcrea was higher than eGFRcys (73 (58-85) vs 63 (50-75) mL/min/1.73 m2 , respectively; P < 0.0001). eGFRcys reclassified significant proportion of patients with T2DM from metformin eligible CKD stages to less or non-eligible stages. The downward reclassification was more frequent in patients older than 80 years (P < 0.01). Cystatin C-based eGFR selects more complicated patients, where lower doses of metformin are possibly advisable. We recommend calculating both eGFRcrea and eGFRcys for metformin dosing in elderly patients with T2DM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035015
003      
CZ-PrNML
005      
20200221132303.0
007      
ta
008      
191007s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bcpt.13132 $2 doi
035    __
$a (PubMed)30218617
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Šálek, Tomáš, $u Department of Clinical Biochemistry and Pharmacology, Tomas Bata Hospital in Zlín a. s., Zlín, Czech Republic. Department of Biomedical sciences, Medical Faculty, University of Ostrava, Ostrava, Zábřeh, Czech Republic. $d 1974- $7 xx0174625
245    10
$a Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients / $c T. Šálek, A. Adamíková,
520    9_
$a The aim of this study was to provide evidence for the hypothesis that estimated glomerular filtration rate from serum Cystatin C (eGFRcys) is better to be determined for all elderly type 2 diabetes mellitus (T2DM) patients based on eGFRcys upward and downward reclassification rate for hypothetical metformin dose reduction by eGFRcys at the GFR decision point of 45 mL/min/1.73 m2 . A total of 265 consecutive T2DM elderly patients (age range 65-91 years) from outpatient diabetic clinic were included in the study. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines for metformin dosing were strictly followed. Estimated glomerular filtration rate from serum creatinine (eGFRcrea) led to results of metformin eligibility. Each of the results of eGFRcrea-based eligibility was further compared to eGFRcys-based eligibility. Creatinine was measured by enzymatic method standardized against international reference material SRM 967. Cystatin C was determined by method traceable to DA ERM 471 international standard. eGFRcrea and eGFRcys were calculated according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. A downward reclassification rate was higher than upward reclassification rate (31 vs 3, respectively; P < 0.0001). The median (IQR) eGFRcrea was higher than eGFRcys (73 (58-85) vs 63 (50-75) mL/min/1.73 m2 , respectively; P < 0.0001). eGFRcys reclassified significant proportion of patients with T2DM from metformin eligible CKD stages to less or non-eligible stages. The downward reclassification was more frequent in patients older than 80 years (P < 0.01). Cystatin C-based eGFR selects more complicated patients, where lower doses of metformin are possibly advisable. We recommend calculating both eGFRcrea and eGFRcys for metformin dosing in elderly patients with T2DM.
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kreatinin $x krev $7 D003404
650    _2
$a cystatin C $x krev $7 D055316
650    _2
$a diabetes mellitus 2. typu $x krev $x farmakoterapie $x patofyziologie $7 D003924
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a hodnoty glomerulární filtrace $x fyziologie $7 D005919
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x aplikace a dávkování $7 D007004
650    _2
$a metformin $x aplikace a dávkování $7 D008687
650    _2
$a chronická renální insuficience $x krev $x patofyziologie $7 D051436
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Adamíková, Alena $u Diabetes Center, Tomas Bata Hospital in Zlín, a. s., Zlín, Czech Republic.
773    0_
$w MED00007578 $t Basic & clinical pharmacology & toxicology $x 1742-7843 $g Roč. 124, č. 3 (2019), s. 298-302
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30218617 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20200221132708 $b ABA008
999    __
$a ok $b bmc $g 1451675 $s 1073565
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 124 $c 3 $d 298-302 $e 20181017 $i 1742-7843 $m Basic & clinical pharmacology & toxicology $n Basic Clin Pharmacol Toxicol $x MED00007578
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...